| Coverage | |||
---|---|---|---|---|
Pretreatment mf prevalence | 60% | 70% | 80% | 90% |
EPIFIL | Â | Â | Â | Â |
   2.5% | 7 | 6 | 5 | 4 |
   5% | 9 | 7 | 6 | 5 |
   10% | 10 | 8 | 7 | 6 |
   15% | 12 | 9 | 8 | 7 |
LYMFASIM a | Â | Â | Â | Â |
   10% (p5 – p95: 8.8% – 11.4%) | 10 | 8 | 6 | 5 |
Details of the 100 simulation runs on which the LYMFASIM estimations were based: | Â | Â | Â | Â |
   Average mf prevalence, 1 year after last treatment round (p5 – p95) | 0.49 (0.29–0.73) | 0.39 (0.25–0.58) | 0.42 (0.24–0.64) | 0.33 (0.22–0.47) |
   Number of runs (%) with zero mf prevalence 40 years after start of treatment, out of the total number that |  |  |  |  |
   - had achieved the 0.5% threshold | 35/51 (69%) | 79/86 (92%) | 62/70 (89%) | 90/97 (93%) |
   - had NOT achieved the 0.5% threshold | 16/49 (33%) | 8/14 (57%) | 18/30 (60%) | 1/3 (33%) |